ATE478064T1 - Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate - Google Patents

Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate

Info

Publication number
ATE478064T1
ATE478064T1 AT07716906T AT07716906T ATE478064T1 AT E478064 T1 ATE478064 T1 AT E478064T1 AT 07716906 T AT07716906 T AT 07716906T AT 07716906 T AT07716906 T AT 07716906T AT E478064 T1 ATE478064 T1 AT E478064T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
pyrimidine derivatives
derivatives used
pyrimidine
kinase
Prior art date
Application number
AT07716906T
Other languages
English (en)
Inventor
Matthew Burger
Zhi-Jie Ni
Sabina Pecchi
Gordana Atallah
Sarah Bartulis
Kelly Frazier
Aaron Smith
Joelle Verhagen
Yanchen Zhang
Allan Wagman
Simon Ng
Keith Pfister
Daniel Poon
Alicia Louie
Teresa Pick
Paul Barsanti
Edwin Iwanowicz
Wendy Fantl
Thomas Hendrickson
Mark Knapp
Hanne Meritt
Charles Voliva
Marion Wiesmann
Xiahua Xin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37951939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE478064(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE478064T1 publication Critical patent/ATE478064T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07716906T 2006-01-20 2007-01-22 Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate ATE478064T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76078906P 2006-01-20 2006-01-20
PCT/US2007/001708 WO2007084786A1 (en) 2006-01-20 2007-01-22 Pyrimidine derivatives used as pi-3 kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE478064T1 true ATE478064T1 (de) 2010-09-15

Family

ID=37951939

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07716906T ATE478064T1 (de) 2006-01-20 2007-01-22 Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate

Country Status (41)

Country Link
US (2) US8217035B2 (de)
EP (2) EP2261223B1 (de)
JP (1) JP5161110B2 (de)
KR (1) KR101353829B1 (de)
CN (1) CN101389622B (de)
AR (2) AR059087A1 (de)
AT (1) ATE478064T1 (de)
AU (1) AU2007206048B2 (de)
BR (1) BRPI0707189B1 (de)
CA (1) CA2636993C (de)
CR (1) CR10163A (de)
CY (1) CY1111091T1 (de)
DE (1) DE602007008529D1 (de)
DK (2) DK2261223T3 (de)
EA (1) EA018083B1 (de)
EC (1) ECSP088630A (de)
ES (2) ES2427624T3 (de)
GE (1) GEP20115147B (de)
GT (1) GT200800143A (de)
HK (1) HK1122031A1 (de)
HN (1) HN2008001144A (de)
HR (2) HRP20100603T1 (de)
IL (1) IL192763A (de)
JO (1) JO2660B1 (de)
MA (1) MA30208B1 (de)
ME (2) MEP3908A (de)
MY (1) MY144233A (de)
NO (1) NO342183B1 (de)
NZ (1) NZ569771A (de)
PE (1) PE20071322A1 (de)
PL (2) PL1984350T3 (de)
PT (2) PT1984350E (de)
RS (2) RS51548B (de)
SI (2) SI1984350T1 (de)
SM (1) SMP200800048B (de)
SV (1) SV2008002984A (de)
TN (1) TNSN08305A1 (de)
TW (2) TW201315723A (de)
UA (1) UA96284C2 (de)
WO (1) WO2007084786A1 (de)
ZA (1) ZA200806017B (de)

Families Citing this family (325)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
MX2009002046A (es) 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
US8173647B2 (en) 2007-02-06 2012-05-08 Gordana Atallah PI 3-kinase inhibitors and methods of their use
EP2142536B1 (de) * 2007-04-20 2015-10-21 Probiodrug AG Aminopyrimidinderivate als glutaminylcyclaseinhibitoren
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
AU2008273891B2 (en) 2007-07-09 2012-01-12 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
US20100311736A1 (en) * 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
WO2009109605A1 (en) 2008-03-05 2009-09-11 Novartis Ag Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
AU2012203914C1 (en) * 2008-03-26 2013-11-28 Novartis Ag 5imidazoquinolines and pyrimidine derivatives as potent modulators of VEGF-driven angiogenic processes
AU2009228797B2 (en) * 2008-03-26 2012-07-19 Novartis Ag 5imidazoquinolines and pyrimidine derivatives as potent modulators of VEGF-driven angiogenic processes
EP2276750A2 (de) * 2008-03-27 2011-01-26 Auckland Uniservices Limited Substituierte pyrimidine und triazine und deren verwendung in der krebstherapie
HUE035029T2 (en) 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US20110105500A1 (en) * 2008-06-27 2011-05-05 S*Bio Pte Ltd. Pyrazine substituted purines
CN102089007B (zh) * 2008-07-11 2013-05-15 诺瓦提斯公司 (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品
TW201010984A (en) * 2008-07-29 2010-03-16 Boehringer Ingelheim Int 5-alkynyl-pyrimidines
WO2010030967A1 (en) * 2008-09-12 2010-03-18 Wyeth Llc 4-aryloxyquinolin-2(1h)-ones as mtor kinase and pi3 kinase inhibitors, for use as anti-cancer agents
EP2617414A3 (de) 2008-10-01 2013-11-06 Novartis AG Geglätteter Antagonismus zur Behandlung von Erkrankungen im Zusammenhang mit dem Hedgehog-Signalweg
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CA2736361C (en) * 2008-10-31 2017-10-10 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
JP5689069B2 (ja) * 2008-11-20 2015-03-25 ジェネンテック， インコーポレイテッド ピラゾロピリジンｐｉ３ｋ阻害剤化合物及び使用方法
EP2379525B1 (de) 2008-12-19 2015-07-29 Boehringer Ingelheim International GmbH Cyclische pyrimidin-4-carbonsäureamide als antagonisten des ccr2-rezeptors zur behandlung von entzündungen, asthma und copd
RU2480463C1 (ru) 2009-03-05 2013-04-27 Дайити Санкио Компани, Лимитед Пиридилокси производные, полезные в качестве активатора/модулятора гамма-рецептора, активируемого пролифератором пероксисом (ppar) гамма
US8461158B2 (en) 2009-03-27 2013-06-11 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
KR20120018761A (ko) * 2009-04-09 2012-03-05 온코타이레온, 인코포레이티드 섬유증을 치료하기 위한 방법 및 ｐｉ-3 키나제 억제제의 조성물
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
BRPI1010979A2 (pt) * 2009-05-15 2018-03-06 Novartis Ag "combinação de um inibidor de fosfoinositídeo 3- quinase e de uma composto antidiabético"
US8173650B2 (en) * 2009-05-27 2012-05-08 Genentech, Inc. Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
TW201105662A (en) 2009-07-07 2011-02-16 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US20120065166A1 (en) * 2009-08-12 2012-03-15 Virginia Espina Bone Modulators And Methods Therewith
CN101993416B (zh) * 2009-08-27 2013-09-11 中国科学院上海药物研究所 喹啉类化合物、其制备方法、包含该化合物的药物组合物及该化合物的用途
SG179085A1 (en) * 2009-09-09 2012-04-27 Avila Therapeutics Inc Pi3 kinase inhibitors and uses thereof
CN102725274A (zh) * 2009-10-16 2012-10-10 Rib-X制药公司 抗微生物化合物和其制备和使用方法
MX2012004341A (es) 2009-10-16 2012-10-05 Rib X Pharmaceuticals Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
ES2524829T3 (es) 2009-12-17 2014-12-12 Boehringer Ingelheim International Gmbh Nuevos antagonistas del receptor CCR2 y usos de los mismos
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
EP2571870B1 (de) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2-antagonisten und verwendungen dafür
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
TW201219353A (en) 2010-09-07 2012-05-16 Daiichi Sankyo Co Ltd Manufacturing method of benzoates
WO2012044727A2 (en) 2010-10-01 2012-04-05 Novartis Ag Manufacturing process for pyrimidine derivatives
WO2012051587A1 (en) * 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers
KR20130101111A (ko) * 2010-11-12 2013-09-12 바이엘 인텔렉쳐 프로퍼티 게엠베하 프로프-2-엔-1-아민으로부터 2,2-디플루오로에틸아민의 제조방법
CN103313714A (zh) * 2010-11-12 2013-09-18 得克萨斯州大学系统董事会 地塞米松组合治疗
BR112013015449A2 (pt) 2010-12-21 2016-09-20 Novartis Ag compostos de bi-heteroarila como inibidores de vps23
JP2014505107A (ja) * 2011-02-11 2014-02-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 過誤腫性腫瘍細胞を阻害する方法
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
SG193982A1 (en) 2011-03-28 2013-11-29 Mei Pharma Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
MX359406B (es) * 2011-07-01 2018-09-27 Novartis Ag Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3kpara usarse en el tratamiento de cáncer.
EP2731941B1 (de) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Neuartige und selektive ccr2-antagonisten
WO2013013188A1 (en) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
BR112014004587A2 (pt) 2011-08-31 2017-03-14 Novartis Ag combinações sinérgicas de inibidores de pi3k- e de mek
CN103764130A (zh) * 2011-09-01 2014-04-30 诺华股份有限公司 用于治疗骨癌或者预防原发性癌细胞转移性播散入骨中的pi3k抑制剂
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
US20140235630A1 (en) * 2011-09-30 2014-08-21 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for the treatment of proliferative diseases
KR20140096035A (ko) * 2011-10-28 2014-08-04 노파르티스 아게 위장 기질 종양을 치료하는 방법
RU2014124184A (ru) * 2011-11-15 2015-12-27 Новартис Аг Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
NZ700928A (en) 2012-04-24 2017-06-30 Vertex Pharma Dna-pk inhibitors
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
RU2630975C2 (ru) 2012-05-16 2017-09-15 Новартис Аг Режим дозирования pi-3 киназы
CA2868392A1 (en) 2012-05-23 2013-11-28 Estelle DOUDEMENT Compositions and methods of obtaining and using endoderm and hepatocyte cells
RU2014154009A (ru) 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
EP2869818A1 (de) 2012-07-06 2015-05-13 Novartis AG Kombination aus einem phosphinositid-3-kinase-hemmer und einem hemmer der il-8-/cxcr-interaktion
WO2014016849A2 (en) 2012-07-23 2014-01-30 Sphaera Pharma Pvt. Ltd. Novel triazine compounds
RU2705095C2 (ru) * 2012-08-16 2019-11-05 Новартис Аг Комбинация ингибитора pik3 и ингибитора с-мет
CN102952086B (zh) * 2012-09-28 2013-08-28 天津科创医药中间体技术生产力促进有限公司 一种2-吗啉基取代嘧啶类化合物的制备方法
ES2644758T3 (es) 2012-10-16 2017-11-30 Tolero Pharmaceuticals, Inc. Moduladores de PKM2 y métodos para su uso
RU2646760C2 (ru) * 2012-10-23 2018-03-07 Новартис Аг Усовершенствованный способ получения 5-(2,6-ди-4-морфолинил-4-пиримидинил)-4-трифторметилпиридин-2-амина
US9296733B2 (en) * 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
JP6322200B2 (ja) 2012-11-16 2018-05-09 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒトホスファチジルイノシトール３−キナーゼデルタのプリン阻害剤
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
EP2742940B1 (de) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane Fumarat zur einmal, zweimal oder dreimal täglichen Verabreichung
WO2014090147A1 (zh) * 2012-12-14 2014-06-19 上海恒瑞医药有限公司 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用
RU2019137208A (ru) 2013-02-20 2020-02-19 Новартис Аг ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
GB201303109D0 (en) * 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
JP6313343B2 (ja) * 2013-03-06 2018-04-18 ノバルティス アーゲー 有機化合物の製剤
LT3527563T (lt) 2013-03-12 2021-12-10 Vertex Pharmaceuticals Incorporated Dnr-pk inhibitoriai
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
WO2014151871A2 (en) 2013-03-14 2014-09-25 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
NZ710929A (en) 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
CN112641787A (zh) 2013-03-21 2021-04-13 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
MY182082A (en) 2013-05-01 2021-01-18 Hoffmann La Roche Biheteroaryl compounds and uses thereof
CN105164114B (zh) * 2013-05-01 2018-03-23 豪夫迈·罗氏有限公司 C‑连接的杂环烷基取代的嘧啶类和它们的用途
CA2909448C (en) * 2013-05-07 2021-10-26 Novartis Ag Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck
CN105283180A (zh) 2013-06-11 2016-01-27 诺华股份有限公司 Pi3k抑制剂与微管去稳定剂的药物组合
WO2014203152A1 (en) 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
JP2016527305A (ja) 2013-08-08 2016-09-08 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤の組合せ
LT3033086T (lt) 2013-08-14 2021-12-27 Novartis Ag Kombinuota terapija vėžiui gydyti
WO2015022657A1 (en) 2013-08-16 2015-02-19 Novartis Ag Pharmaceutical combinations
MX2016003046A (es) 2013-09-09 2016-09-08 Melinta Therapeutics Inc Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos.
US10106543B2 (en) 2013-09-09 2018-10-23 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CN103483345B (zh) * 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
PT3424920T (pt) 2013-10-17 2020-07-07 Vertex Pharma Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk
EP3094340A1 (de) * 2014-01-15 2016-11-23 Novartis AG Pharmazeutische kombinationen
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ES2921874T3 (es) 2014-02-28 2022-09-01 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
JP6513105B2 (ja) 2014-04-22 2019-05-15 ウニヴェルズィテート バーゼル トリアジン、ピリミジン及びピリジン誘導体の新規製造方法
WO2016001789A1 (en) * 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
WO2016001341A1 (en) * 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
CN117088931A (zh) 2014-08-12 2023-11-21 莫纳什大学 定向淋巴的前药
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
CN104151256B (zh) * 2014-08-14 2016-08-24 西安交通大学 二取代苯甲酰胺类化合物及其合成方法和应用
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
CN105461714B (zh) * 2014-09-29 2017-11-28 山东轩竹医药科技有限公司 并环类pi3k抑制剂
EP3200775B1 (de) 2014-10-03 2019-11-20 Novartis AG Kombinationstherapien
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
TN2017000173A1 (en) 2014-11-14 2018-10-19 Novartis Ag Antibody drug conjugates
CN105085476B (zh) * 2014-11-24 2018-03-09 苏州晶云药物科技有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
US10689459B2 (en) * 2014-12-12 2020-06-23 Novartis Ag Treatment of breast cancer brain metastases
US10227324B2 (en) 2014-12-17 2019-03-12 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
DK3237418T3 (da) 2014-12-23 2019-05-13 Novartis Ag Triazolopyrimidinforbindelser og anvendelser deraf
CN105832741A (zh) * 2015-01-16 2016-08-10 复旦大学 Pi3k抑制剂与紫杉醇的药物组合物及其在制备抗肿瘤药物中的应用
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
KR102629269B1 (ko) 2015-02-27 2024-01-24 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
SG11201707346RA (en) 2015-03-11 2017-10-30 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
US9481665B2 (en) * 2015-03-13 2016-11-01 Yong Xu Process for preparing PI3K inhibitor buparsilib
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
KR20170129757A (ko) 2015-03-25 2017-11-27 노파르티스 아게 Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
EP3878465A1 (de) 2015-07-29 2021-09-15 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen tim-3
EP3964528A1 (de) 2015-07-29 2022-03-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen lag-3
CN105001151B (zh) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 布帕尼西中间体及其制备方法
US20190060309A1 (en) 2015-08-28 2019-02-28 Novartis Ag Mdm2 inhibitors and combinations thereof
WO2017040757A1 (en) 2015-09-02 2017-03-09 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2017041139A1 (en) 2015-09-08 2017-03-16 Monash University Lymph directing prodrugs
WO2017044720A1 (en) 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
PT3364958T (pt) * 2015-10-23 2023-04-10 Navitor Pharm Inc Moduladores de interação sestrina-gator2 e utilizações dos mesmos
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MX2018005298A (es) 2015-11-02 2018-06-22 Novartis Ag Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
AU2016348391A1 (en) 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
WO2017093905A1 (en) 2015-12-03 2017-06-08 Novartis Ag Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
CN106883185B (zh) * 2015-12-15 2021-07-09 重庆博腾制药科技股份有限公司 一种4-氯-2-三氟甲基嘧啶的制备方法
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
US10954220B2 (en) 2016-03-09 2021-03-23 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
PL3426244T3 (pl) 2016-03-09 2023-09-25 Raze Therapeutics, Inc. Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
EP3231799A1 (de) * 2016-04-14 2017-10-18 Universität Basel 4-(azetidin-1-yl)pyrimidin- derivate mit anti-mitotischer und anti-proliferativer aktivität
AU2017265383B2 (en) * 2016-05-18 2022-07-28 Torqur Ag Treatment of neurological disorders
MX2018014167A (es) 2016-05-18 2019-08-16 Piqur Therapeutics Ag Tratamiento de lesiones de la piel.
EP3441387A1 (de) 2016-06-02 2019-02-13 Shanghai Haiyan Pharmaceutical Technology Co. Ltd. Pi3k-hemmer und pharmazeutisch akzeptables salz, polykristalline form und verwendung davon
EP3472166A1 (de) 2016-06-20 2019-04-24 Novartis AG Imidazopyrimidinverbindungen zur behandlung von krebs
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
EP3472168B1 (de) 2016-06-20 2024-01-10 Novartis AG Kristalline formen einer triazolopyrimidinverbindung
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106905294A (zh) * 2016-07-08 2017-06-30 苏州科睿思制药有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
JP2019536471A (ja) 2016-09-27 2019-12-19 セロ・セラピューティクス・インコーポレイテッドＣＥＲＯ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． キメラエンガルフメント受容体分子
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
CA3039202A1 (en) 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US10414727B2 (en) 2016-11-08 2019-09-17 Navitor Pharmaceuticals, Inc. Phenyl amino piperidine mTORC inhibitors and uses thereof
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
CN110603261A (zh) 2016-12-23 2019-12-20 拜斯科阿迪有限公司 具有新型键结构的肽衍生物
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
EP3592868B1 (de) 2017-03-06 2022-11-23 Novartis AG Verfahren zur behandlung von krebs mit reduzierter ubb-expression
AR111233A1 (es) 2017-03-08 2019-06-19 Nimbus Lakshmi Inc Inhibidores de tyk2, usos y métodos para la producción de los mismos
EP3375784A1 (de) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridonderivate
EP3375778A1 (de) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidinderivate
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
CN116370448A (zh) 2017-04-26 2023-07-04 纳维托制药有限公司 Sestrin-gator2相互作用的调节剂及其用途
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
MX2019013862A (es) 2017-05-23 2020-01-20 Mei Pharma Inc Terapia de combinacion.
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
EP3642240A1 (de) 2017-06-22 2020-04-29 Novartis AG Antikörpermoleküle gegen cd73 und verwendungen davon
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
CN117946115A (zh) 2017-07-28 2024-04-30 武田药品工业株式会社 Tyk2抑制剂与其用途
BR112020002984A2 (pt) 2017-08-14 2020-08-11 Mei Pharma, Inc. terapia combinada
EP3668550A1 (de) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclische peptidligand-prr-a-konjugate und deren verwendung
US20200291096A1 (en) 2017-08-14 2020-09-17 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
US10800774B2 (en) * 2017-08-17 2020-10-13 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
WO2019046491A1 (en) 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11859252B2 (en) 2017-09-08 2024-01-02 Genentech, Inc. Diagnostic and therapeutic methods for cancer
AU2018338314A1 (en) 2017-09-22 2020-04-09 Kymera Therapeutics, Inc Protein degraders and uses thereof
EP3684366A4 (de) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. Crbn-liganden und verwendungen davon
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
CN109651341A (zh) * 2017-10-11 2019-04-19 上海医药工业研究院 二吗啉氰基嘧(吡)啶类衍生物及作为抗肿瘤药物应用
EP3694511A1 (de) 2017-10-13 2020-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationsbehandlung von pankreasarzinom
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
EP3727362A4 (de) 2017-12-19 2021-10-06 PureTech LYT, Inc. Lipidprodrugs von mycophenolsäure und ihre verwendungen
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
BR112020012651A2 (pt) 2017-12-22 2020-12-01 Ravenna Pharmaceuticals, Inc. compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
IL275490B2 (en) 2017-12-22 2024-05-01 Ravenna Pharmaceuticals Inc Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
JP2021508703A (ja) 2017-12-26 2021-03-11 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
EP3737666A4 (de) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Proteinabbaumittel und verwendungen davon
EP3737675A4 (de) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn-liganden und verwendungen davon
BR112020015328A2 (pt) 2018-01-29 2020-12-08 Merck Patent Gmbh Inibidores de gcn2 e usos dos mesmos
CA3089769A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
KR20200140262A (ko) 2018-02-27 2020-12-15 아텍스 바이오파마 인코포레이티드 Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
JP7444781B2 (ja) 2018-03-28 2024-03-06 セロ・セラピューティクス・インコーポレイテッド 細胞免疫療法組成物およびその使用
AU2019243153A1 (en) 2018-03-28 2020-10-01 Cero Therapeutics, Inc. Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
AU2019247498A1 (en) 2018-04-05 2020-11-26 Sumitomo Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
WO2019194220A1 (ja) * 2018-04-06 2019-10-10 日本曹達株式会社 （ヘテロ）アリールスルホンアミド化合物および有害生物防除剤
EP3774783A1 (de) * 2018-04-10 2021-02-17 Neuropore Therapies, Inc. Trisubstituierte aryl- und heteroarylderivate als modulatoren der pi3-kinase- und autophagiesignalwege
EP3774792B1 (de) 2018-04-10 2022-09-14 Neuropore Therapies, Inc. Morpholinderivate als hemmer von vps34
IL278142B2 (en) 2018-04-24 2023-11-01 Merck Patent Gmbh Antiproliferative compounds and their uses
ES2969982T3 (es) 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019241789A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN108864067B (zh) * 2018-06-20 2020-05-12 郑州大学 一种2-炔丙巯基-5-氰基嘧啶类衍生物及其制备方法和应用
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
EP3817748A4 (de) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. Tricyclische crbn-liganden und verwendungen davon
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
AU2019322325B2 (en) 2018-08-17 2022-01-20 Novartis Ag Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3846793B1 (de) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e-inhibitoren und verwendungen davon
AU2019360941A1 (en) 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CN113164414A (zh) 2018-10-24 2021-07-23 纳维托制药有限公司 多晶型化合物和其用途
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
WO2020112937A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
SG11202105424PA (en) 2018-11-30 2021-06-29 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3670659A1 (de) 2018-12-20 2020-06-24 Abivax Biomarker und verwendungen bei der behandlung von viralen infektionen, entzündlichen oder krebserkrankungen
EP3898697A2 (de) 2018-12-21 2021-10-27 Novartis AG Antikörper gegen pmel17 und ihre konjugate
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN109705033B (zh) * 2019-01-22 2021-03-30 杭州壹瑞医药科技有限公司 N-杂芳基磺酰胺类衍生物及制备和应用
CN109651297B (zh) * 2019-01-22 2022-05-27 杭州壹瑞医药科技有限公司 一种n-苄基-n-芳基磺酰胺类衍生物及制备和应用
JP2022518505A (ja) 2019-01-23 2022-03-15 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
MX2021009371A (es) 2019-02-12 2021-09-10 Sumitomo Pharma Oncology Inc Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos.
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
CA3133460A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020201753A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
SG11202110829YA (en) 2019-04-05 2021-10-28 Kymera Therapeutics Inc Stat degraders and uses thereof
MX2021014441A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2021001431A1 (en) 2019-07-02 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer
US20220354863A1 (en) 2019-07-02 2022-11-10 Inserm (Institut National De La Santè Et De La Recherch Médicale) Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
US20220354452A1 (en) 2019-07-02 2022-11-10 Inserm (Institut National De La Santé Et De La Rechrche Médical) Use of ultrafast elasticity imaging for detecting pancreatic cancers
KR20220028075A (ko) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4028385A4 (de) 2019-09-11 2023-11-08 Vincere Biosciences, Inc. Usp30-inhibitoren und verwendungen davon
CA3150108A1 (en) 2019-09-13 2021-03-18 Neelu Kaila HPK1 ANTAGONISTS AND THEIR USES
EP4031578A1 (de) 2019-09-18 2022-07-27 Novartis AG Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
WO2021057853A1 (en) 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof
WO2021067875A1 (en) 2019-10-03 2021-04-08 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
US11723890B2 (en) 2019-11-01 2023-08-15 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
TW202134234A (zh) 2019-12-05 2021-09-16 美商奈維特製藥公司 雷帕黴素類似物及其用途
IL293917A (en) 2019-12-17 2022-08-01 Kymera Therapeutics Inc Iraq joints and their uses
EP4076524A4 (de) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. Irak-degrader und verwendungen davon
WO2021133920A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
CA3166908A1 (en) 2020-02-05 2021-08-12 Daniel Kenneth BONNER Lipid prodrugs of neurosteroids
WO2021159993A1 (en) * 2020-02-14 2021-08-19 Pharmablock Sciences (Nanjing) , Inc. Inhibitors of interleukin-1 receptor associated kinase (irak) /fms-like receptor tyrosine kinase (flt3), pharmaceutical products thereof, and methods thereof
CA3170411A1 (en) 2020-03-03 2021-09-10 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
CN115776887A (zh) 2020-03-19 2023-03-10 凯麦拉医疗公司 Mdm2降解剂和其用途
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
KR20210158019A (ko) 2020-06-23 2021-12-30 주식회사 온코빅스 포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
TW202227089A (zh) 2020-11-30 2022-07-16 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
KR20230131189A (ko) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
WO2022167445A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
JP2024505571A (ja) 2021-02-02 2024-02-06 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
IL304905A (en) 2021-02-15 2023-10-01 Kymera Therapeutics Inc IRAK4 joints and their uses
AU2022227021A1 (en) 2021-02-26 2023-09-21 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
JP2024509192A (ja) 2021-03-05 2024-02-29 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
EP4310081A1 (de) * 2021-03-18 2024-01-24 Suzhou Guokuang Pharmtech. Co., Ltd. Kleinmoleküliges ctla-4-abbaumittel und anwendung davon
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
EP4323526A1 (de) 2021-04-16 2024-02-21 Novartis AG Antikörper-wirkstoff-konjugate und verfahren zur herstellung davon
KR20230172548A (ko) 2021-04-16 2023-12-22 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
WO2023010097A1 (en) 2021-07-28 2023-02-02 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
AU2022334296A1 (en) 2021-08-25 2024-03-07 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US20230134932A1 (en) 2021-08-25 2023-05-04 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2023107603A1 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Pyrimidines and methods of their use
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN114213340B (zh) 2022-02-22 2022-06-07 北京蓝晶微生物科技有限公司 2,4-二氨基嘧啶氧化物的制备方法
CN114591326B (zh) * 2022-02-28 2024-02-27 上海筛杰生物医药有限公司 Cct-251921的中间体及其制备方法
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB581334A (en) 1943-09-29 1946-10-09 Francis Henry Swinden Curd New pyrimidine compounds
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
AT340933B (de) * 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4329726A (en) * 1978-12-01 1982-05-11 Raychem Corporation Circuit protection devices comprising PTC elements
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
EP0303697B1 (de) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivate des physiologisch aktiven mittels k-252
US4994386A (en) 1987-07-13 1991-02-19 Pharmacia Diagnostics, Inc. Production of HBLV virus in the HSB-2 cell line
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
WO1989007105A1 (en) 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5451700A (en) 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0540185A1 (de) 1991-10-10 1993-05-05 Schering Corporation N-substituierte Staurosporin-N-oxid-Derivate
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
WO1993008809A1 (en) 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
WO1994005304A1 (en) 1992-08-31 1994-03-17 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
EP0630898B1 (de) 1992-09-21 2001-11-28 Kyowa Hakko Kogyo Co., Ltd. Heilmittel für thrombozytopenia
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
WO1995002597A1 (en) 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
DK0817627T3 (da) 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
DK0817775T3 (da) 1995-03-30 2001-11-19 Pfizer Quinazolinderivater
KR100275300B1 (ko) 1995-04-13 2000-12-15 고바야시 유키오 신규 4,6-디아릴피리미딘 유도체 및 그 염(novel 4,6-diarylpyrimidine derivatives and salts thereof)
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU6888196A (en) 1995-08-11 1997-03-12 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
ATE321757T1 (de) 1995-12-08 2006-04-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinonderivate als farnesyl protein transferase inhibitoren
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
DE69734589T2 (de) 1996-08-02 2006-08-10 Genesense Technologies Inc., Markham Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase
JP3734907B2 (ja) * 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
ES2253821T3 (es) 1997-07-12 2006-06-01 Cancer Research Technology Limited Derivados de purina inhibidores de quinasa que depende de ciclina.
DK1020462T3 (da) * 1997-07-24 2004-04-26 Zenyaku Kogyo Kk Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
DE69906397T2 (de) * 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
SK287132B6 (sk) 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6489344B1 (en) 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
US6495558B1 (en) * 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
JP2002535318A (ja) 1999-01-22 2002-10-22 アムジエン・インコーポレーテツド キナーゼ阻害薬
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
BR0010304A (pt) 1999-05-04 2002-02-13 Schering Corp Derivados de piperazina úteis como antagonistas do ccr5
ES2246233T3 (es) 1999-05-04 2006-02-16 Schering Corporation Derivados de piperidina utiles como antagonistas de ccr5.
CH694589A5 (de) 1999-06-25 2005-04-15 Genentech Inc Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern.
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
JP2003503354A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
CA2379035A1 (en) 1999-07-13 2001-01-18 Shiro Akinaga Staurosporin derivatives
WO2001005783A1 (en) 1999-07-15 2001-01-25 Pharmacopeia, Inc. Bradykinin b1 receptor antagonists
EP1676845B1 (de) 1999-11-05 2008-06-11 AstraZeneca AB Neue Quinazolin-Derivate
ES2290117T3 (es) 2000-02-15 2008-02-16 Sugen, Inc. Inhibidores de proteina quinasa 2-indolina sustituida con pirrol.
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
CA2406847C (en) 2000-04-12 2009-11-17 Genaera Corporation Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterols
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
AU4114201A (en) 2000-04-28 2001-11-12 Tanabe Seiyaku Co Cyclic compounds
WO2002000647A1 (en) * 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
KR100815681B1 (ko) 2000-06-30 2008-03-20 글락소 그룹 리미티드 퀴나졸린 디토실레이트 염 화합물
AU9502601A (en) 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3
SG174632A1 (en) 2000-09-11 2011-10-28 Novartis Vaccines & Diagnostic Quinolinone derivatives
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
KR100947185B1 (ko) 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
EP1392859B1 (de) 2001-01-16 2006-05-10 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
EP1395561A1 (de) * 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Carbamat und oxamid verbindungen als inhibitoren der cytokinproduktion
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
WO2003004505A1 (en) 2001-07-02 2003-01-16 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
US6603000B2 (en) * 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
EP1485082A4 (de) 2002-02-19 2009-12-30 Xenoport Inc Syntheseverfahren für prodrugs von 1-acyl-alkyl derivaten und ihre zusammensetzungen
ATE466580T1 (de) * 2002-03-15 2010-05-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
EP1485380B1 (de) * 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazine als proteinkinasehemmer
DE60314603T2 (de) * 2002-03-15 2008-02-28 Vertex Pharmaceuticals Inc., Cambridge Zusammensetzungen brauchbar als protein-kinase-inhibitoren
EP1485381B8 (de) * 2002-03-15 2010-05-12 Vertex Pharmaceuticals Incorporated Azolylaminoazine als inhibitoren von proteinkinasen
ES2336094T3 (es) 2002-03-29 2010-04-08 Novartis Vaccines And Diagnostics, Inc. Benzazoles sustituidos y uso de los mismos como inhibidores de quinasa raf.
US6900342B2 (en) 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
JP2006515274A (ja) 2002-10-08 2006-05-25 マサチューセッツ・インスティテュート・オブ・テクノロジー コレステロール輸送の調節のための化合物
CA2507100C (en) * 2002-11-21 2012-10-09 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (de) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Verwendung von tryptanthrin-verbindungen zur immunverstärkung
CA2519677A1 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocycles as sodium channel blockers
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
JP2007523875A (ja) 2003-07-15 2007-08-23 ニューロジェン・コーポレーション バニロイド受容体リガンドとしての置換ピリミジン−４−イルアミン類縁体
AU2004257289A1 (en) 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
KR20080083188A (ko) 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8173647B2 (en) * 2007-02-06 2012-05-08 Gordana Atallah PI 3-kinase inhibitors and methods of their use
JP2014505107A (ja) 2011-02-11 2014-02-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 過誤腫性腫瘍細胞を阻害する方法

Also Published As

Publication number Publication date
IL192763A0 (en) 2009-02-11
GEP20115147B (en) 2011-01-25
SMP200800048B (it) 2009-07-14
HRP20130796T1 (en) 2013-09-30
MY144233A (en) 2011-08-15
PL1984350T3 (pl) 2011-02-28
TW200808786A (en) 2008-02-16
EP2261223A1 (de) 2010-12-15
SMAP200800048A (it) 2008-08-13
ES2351172T3 (es) 2011-02-01
EP2261223B1 (de) 2013-06-12
RS52928B (en) 2014-02-28
DK1984350T3 (da) 2010-11-15
CA2636993A1 (en) 2007-07-26
AR112118A2 (es) 2019-09-25
ZA200806017B (en) 2009-12-30
SI2261223T1 (sl) 2013-10-30
WO2007084786A1 (en) 2007-07-26
ES2427624T3 (es) 2013-10-31
EP1984350A1 (de) 2008-10-29
NO342183B1 (no) 2018-04-09
TNSN08305A1 (en) 2009-12-29
PE20071322A1 (es) 2008-01-27
SI1984350T1 (sl) 2010-12-31
IL192763A (en) 2013-04-30
CN101389622A (zh) 2009-03-18
US20120225859A1 (en) 2012-09-06
TWI385170B (zh) 2013-02-11
JO2660B1 (en) 2012-06-17
DK2261223T3 (da) 2013-09-23
CN101389622B (zh) 2013-04-17
PL2261223T3 (pl) 2013-12-31
CA2636993C (en) 2014-02-25
US20100249126A1 (en) 2010-09-30
US8563549B2 (en) 2013-10-22
GT200800143A (es) 2009-06-11
MEP3908A (xx) 2010-02-10
NO20083389L (no) 2008-09-19
CY1111091T1 (el) 2015-06-11
HN2008001144A (es) 2011-04-08
RS51548B (en) 2011-06-30
EP1984350B1 (de) 2010-08-18
CR10163A (es) 2008-09-17
US8217035B2 (en) 2012-07-10
ME00012B (me) 2010-02-10
PT1984350E (pt) 2010-11-11
JP2009527464A (ja) 2009-07-30
KR101353829B1 (ko) 2014-01-21
PT2261223E (pt) 2013-09-16
BRPI0707189A8 (pt) 2018-01-02
EA200801680A1 (ru) 2008-12-30
UA96284C2 (ru) 2011-10-25
BRPI0707189A2 (pt) 2011-04-26
AU2007206048A1 (en) 2007-07-26
HK1122031A1 (en) 2009-05-08
TW201315723A (zh) 2013-04-16
KR20080096776A (ko) 2008-11-03
MA30208B1 (fr) 2009-02-02
HRP20100603T1 (hr) 2010-12-31
DE602007008529D1 (de) 2010-09-30
AR059087A1 (es) 2008-03-12
BRPI0707189B1 (pt) 2021-12-21
NZ569771A (en) 2011-07-29
ECSP088630A (es) 2008-08-29
SV2008002984A (es) 2010-08-17
JP5161110B2 (ja) 2013-03-13
EA018083B1 (ru) 2013-05-30
AU2007206048B2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
ATE478064T1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE510825T1 (de) Acylaminopyrazole als fgfr-inhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
DE602007008837D1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
CR10369A (es) Pyrimidine derivatives as pi3k inhibitors
ATE549340T1 (de) Spiroindolinon-derivate als mdm2-p53 inhibitoren
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
ATE555104T1 (de) 5-substituierte chinazolinon-derivate als antitumorverbindungen
ATE531705T1 (de) Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
DE602006011363D1 (de) Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
ATE493411T1 (de) Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer
ATE483711T1 (de) Spiroindolinonderivate
ATE517101T1 (de) Als mmp-inhibitoren verwendete hydantoinderivate
ATE469905T1 (de) Pyridopyrimidinonderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1984350

Country of ref document: EP